AU2012296954B2 - Carrier-linked treprostinil prodrugs - Google Patents

Carrier-linked treprostinil prodrugs Download PDF

Info

Publication number
AU2012296954B2
AU2012296954B2 AU2012296954A AU2012296954A AU2012296954B2 AU 2012296954 B2 AU2012296954 B2 AU 2012296954B2 AU 2012296954 A AU2012296954 A AU 2012296954A AU 2012296954 A AU2012296954 A AU 2012296954A AU 2012296954 B2 AU2012296954 B2 AU 2012296954B2
Authority
AU
Australia
Prior art keywords
carrier
alkyl
formula
ral2
linked treprostinil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012296954A
Other languages
English (en)
Other versions
AU2012296954A1 (en
Inventor
Nicola BISEK
Ulrich Hersel
Oliver Keil
Torben Lessmann
Guillaume Maitro
Harald Rau
Kennett Sprogoe
Thomas Wegge
Joachim Zettler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendis Pharma AS
Original Assignee
Ascendis Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma AS filed Critical Ascendis Pharma AS
Publication of AU2012296954A1 publication Critical patent/AU2012296954A1/en
Application granted granted Critical
Publication of AU2012296954B2 publication Critical patent/AU2012296954B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2012296954A 2011-08-12 2012-08-10 Carrier-linked treprostinil prodrugs Ceased AU2012296954B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11177409 2011-08-12
EP11177409.7 2011-08-12
EP11195615 2011-12-23
EP11195615.7 2011-12-23
EP12165508.8 2012-04-25
EP12165508 2012-04-25
PCT/EP2012/065745 WO2013024052A1 (en) 2011-08-12 2012-08-10 Carrier-linked treprostinil prodrugs

Publications (2)

Publication Number Publication Date
AU2012296954A1 AU2012296954A1 (en) 2014-02-20
AU2012296954B2 true AU2012296954B2 (en) 2016-09-15

Family

ID=46690494

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012296954A Ceased AU2012296954B2 (en) 2011-08-12 2012-08-10 Carrier-linked treprostinil prodrugs

Country Status (14)

Country Link
US (2) US9561287B2 (enExample)
EP (1) EP2741781A1 (enExample)
JP (1) JP6092867B2 (enExample)
KR (1) KR101997939B1 (enExample)
CN (1) CN103857413A (enExample)
AU (1) AU2012296954B2 (enExample)
BR (1) BR112014003225A2 (enExample)
CA (1) CA2843883C (enExample)
HK (1) HK1198359A1 (enExample)
IL (1) IL230712A (enExample)
IN (1) IN2014CN00989A (enExample)
MX (1) MX349950B (enExample)
WO (1) WO2013024052A1 (enExample)
ZA (1) ZA201400977B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1198359A1 (en) * 2011-08-12 2015-04-10 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
AU2013254756B2 (en) * 2012-04-25 2017-03-30 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US9913912B2 (en) 2012-12-07 2018-03-13 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP4137127A1 (en) 2013-01-11 2023-02-22 Corsair Pharma, Inc. Prodrugs of treprostinil
CA2908244C (en) * 2013-03-25 2021-04-20 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
CN105407883A (zh) * 2013-04-30 2016-03-16 联合治疗学有限公司 控释药物制剂
KR102296259B1 (ko) 2013-10-25 2021-08-30 인스메드 인코포레이티드 프로스타사이클린 화합물, 조성물 및 이의 사용 방법
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
WO2015192030A1 (en) * 2014-06-13 2015-12-17 United Therapeutics Corporation Treprostinil formulations
WO2016010538A1 (en) * 2014-07-16 2016-01-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (zh) 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 曲前列環素二乙醇胺之合成方法及新穎中間體
US10632129B2 (en) * 2014-12-03 2020-04-28 Steadymed Ltd. Preservative-free treprostinil formulations and methods and devices for use with same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11389510B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
MX2018008050A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
SI3400019T1 (sl) 2016-01-08 2023-01-31 Ascendis Pharma Growth Disorders Division A/S Predzdravila CNP s povezavo nosilca na obročni ostanek
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
IL297375B2 (en) 2016-01-08 2024-02-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low NPR–C binding
CN109069659B (zh) 2016-03-01 2022-04-19 阿森迪斯药物骨疾病股份有限公司 Pth前药
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
SI3512495T1 (sl) * 2016-09-15 2023-01-31 Camurus Ab Formulacije prostaciklinskih analogov
NZ792622A (en) 2016-09-29 2025-08-29 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
IL304086A (en) 2016-09-29 2023-08-01 Ascendis Pharma Bone Diseases As Dosing regimen for a controlled-release PTH compound
DK3518982T3 (da) 2016-09-29 2025-02-03 Ascendis Pharma Bone Diseases As Pth-forbindelser med kontrolleret frigivelse
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
AU2019270464B2 (en) 2018-05-18 2024-09-26 Ascendis Pharma Bone Diseases A/S Starting dose of PTH conjugates
IL281690B2 (en) 2018-09-26 2025-01-01 Ascendis Pharma As New hydrogel bracelets
IL281695B2 (en) 2018-09-26 2025-08-01 Ascendis Pharma As Degradable hyaluronic acid hydrogels
CA3114056A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
CA3125479A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
CA3125488A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
MX2021007706A (es) 2019-01-04 2021-08-05 Ascendis Pharma Oncology Div A/S Conjugados de agonistas de receptor de reconocimiento de patron.
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
MY209748A (en) 2019-02-11 2025-07-31 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
WO2020254611A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
TW202114660A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 酪胺酸激酶抑制劑結合物
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
CA3161101A1 (en) 2020-01-13 2021-07-22 Kennett Sprogoe Hypoparathyroidism treatment
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
CN116113415A (zh) 2020-06-09 2023-05-12 联合治疗公司 曲前列尼尔的富马酰基二酮哌啶前药
MX2023003540A (es) 2020-09-28 2023-04-21 Ascendis Pharma Bone Diseases As Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo.
JP7138685B2 (ja) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
TW202246206A (zh) * 2021-03-16 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種曲前列環素衍生物及其用途
IL311539A (en) 2021-09-22 2024-05-01 Ascendis Pharma Bone Diseases As Long-acting pth compound treatments
AU2022409306A1 (en) 2021-12-13 2024-06-06 Ascendis Pharma Oncology Division A/S Cancer treatments with tlr7/8 agonists
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
CN116444377A (zh) * 2022-01-07 2023-07-18 广州楷石医药有限公司 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途
IL316466A (en) 2022-05-23 2024-12-01 Ascendis Pharma Growth Disorders As Liquid pharmaceutical formulations of cnp compounds
AU2023374533A1 (en) 2022-11-02 2025-04-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
CN121219011A (zh) 2023-03-20 2025-12-26 阿森迪斯药物生长障碍股份有限公司 治疗患有软骨发育不全患者胸腰椎畸形的方法
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057701A1 (en) * 1999-03-31 2000-10-05 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
CA2843439A1 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
ES2331187T3 (es) * 2003-12-16 2009-12-23 United Therapeutics Corporation Utilizacion de treprostinil para mejorar las funciones renales.
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1625856A1 (en) 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel polymeric conjugates of a prodrug
EP2120961A1 (en) * 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
EP2173890B1 (en) * 2007-06-21 2011-03-16 Technische Universität München Biological active proteins having increased in vivo and/or vitro stability
CA2721947C (en) 2008-04-29 2016-03-08 Ascendis Pharma As Pegylated recombinant human growth hormone compounds
US8575102B2 (en) 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage
US8637466B2 (en) * 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US20110166063A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
EP2370068A4 (en) * 2008-12-10 2015-09-23 Paka Pulmonary Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
SG177761A1 (en) * 2009-07-31 2012-03-29 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
EP2485767A1 (en) * 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
HK1198359A1 (en) * 2011-08-12 2015-04-10 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057701A1 (en) * 1999-03-31 2000-10-05 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Also Published As

Publication number Publication date
IL230712A0 (en) 2014-03-31
EP2741781A1 (en) 2014-06-18
HK1198359A1 (en) 2015-04-10
JP6092867B2 (ja) 2017-03-08
KR20140070545A (ko) 2014-06-10
BR112014003225A2 (pt) 2017-03-01
JP2014527050A (ja) 2014-10-09
MX349950B (es) 2017-08-22
CA2843883C (en) 2020-04-28
KR101997939B1 (ko) 2019-07-08
CN103857413A (zh) 2014-06-11
IN2014CN00989A (enExample) 2015-04-10
IL230712A (en) 2017-08-31
US10729778B2 (en) 2020-08-04
AU2012296954A1 (en) 2014-02-20
WO2013024052A1 (en) 2013-02-21
US9561287B2 (en) 2017-02-07
MX2014001497A (es) 2014-04-25
ZA201400977B (en) 2017-11-29
CA2843883A1 (en) 2013-02-21
US20140296150A1 (en) 2014-10-02
US20190105400A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
AU2012296954B2 (en) Carrier-linked treprostinil prodrugs
AU2012296953B2 (en) Sustained release composition of prostacyclin
AU2013353985B2 (en) Carrier-linked prostanoid prodrugs
AU2012296955B2 (en) Carrier-linked prodrugs having reversible carboxylic ester linkages
TW201703793A (zh) 聚乙二醇化介白素-11之組合物及方法
HK1197733A (en) Sustained release composition of prostacyclin
HK40026763A (en) Carrier-linked prodrugs having reversible carboxylic ester linkages
HK1197731A (en) Carrier-linked treprostinil prodrugs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired